Downloads provided by UsageCounts
handle: 10261/173484 , 10261/173479
[ES] Aminofenotiazinas para la modulación del número de sinapsis. La presente invención se refiere al uso de un grupo de compuestos con núcleo de fenotiazina con la siguiente fórmula general (I): para el tratamiento de enfermedades del sistema nervioso central que presentan anormalidades en la sinapsis, tales como autismo o síndrome de frágil X. Los compuestos de la invención intervienen en la interacción de las proteínas NCS1 y Ric8 implicadas en el proceso de sinaptogénesis.
[EN] The invention relates to the use of a group of compounds with a phenothiazine nucleus of general formula (I) for the treatment of diseases of the central nervous system which present synapse abnormalities, such as autism or fragile X syndrome. The compounds according to the invention intervene in the interaction of the NCS1 and Ric8 proteins involved in the process of synaptogenesis.
Consejo Superior de Investigaciones Científicas (España)
B1 Patente sin examen previo
Peer reviewed
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 56 | |
| downloads | 141 |

Views provided by UsageCounts
Downloads provided by UsageCounts